Carbamazepine Extended-Release Tablets
»Carbamazepine Extended-Release Tablets contain not less than 90.0percent and not more than 110.0percent of the labeled amount of carbamazepine (C15H12N2O).
Packaging and storage— Preserve in tight containers at controlled room temperature.
Identification—
A: Ultraviolet Absorption á197Uñ
Solution— Use the Test solutionprepared as directed in the test for Uniformity of dosage units.
B: The retention time of the major peak in the chromatogram of the Assay preparationcorresponds to that in the chromatogram of the Standard preparation,as obtained in the Assay.
Drug release á724ñ
Medium: water;900mL,1800mLfor 400-mg Tablets.
Apparatus 1: 100rpm.
Times: 3,6,12,and 24hours.
Procedure— Determine the amount of C15H12N2Odissolved by employing UVabsorption at the wavelength of maximum absorbance at about 284nm on filtered portions of the solution under test,suitably diluted with Dissolution Medium,if necessary,in comparison with a Standard solution having a known concentration of USP Carbamazepine RSin the same Medium.
Tolerances— The percentages (Q)of the labeled amount of C15H12N2Odissolved at the times specified conform to Acceptance Table 1.
Time (hours) Amount dissolved
3 between 10%and 35%
6 between 35%and 65%
12 between 65%and 90%
24 not less than 75%
Uniformity of dosage units á905ñ: meet the requirements.
PROCEDUREFOR CONTENT UNIFORMITY
Standard stock solution— Dissolve an accurately weighed quantity of USP Carbamazepine RSin methanol to obtain a solution containing 2mg per mL.
Standard solution— Quantitatively dilute an accurately measured volume of Standard stock solutionwith methanol to obtain a solution having a known concentration of 10µg per mL.
Test solution— Finely powder 1Tablet,and quantitatively transfer the powder,with the aid of methanol,to a 100-mLvolumetric flask.Add about 70mLof methanol,and shake by mechanical means for 60minutes.Sonicate for 15minutes,and dilute with methanol to volume.Allow to stand for 10to 15minutes.Dilute a portion of the clear solution quantitatively,and stepwise if necessary,with methanol to obtain a solution containing about 10µg of carbamazepine per mL.
Procedure— Concomitantly determine the absorbances of the Test solutionand the Standard solutionby employing UVabsorption at the wavelength of maximum absorbance at about 284nm,using methanol as a blank.Calculate the quantity,in mg,of carbamazepine (C15H12N2O)in the Tablet taken by the formula:
(LC/D)(AU/AS),
in which Lis the labeled quantity,in mg,of carbamazepine in the Tablet;Cis the concentration,in µg per mL,of USP Carbamazepine RSin the Standard solution;Dis the concentration,in µg per mL,of the Test solution,based on the labeled quantity per Tablet and the extent of dilution;and AUand ASare the absorbances obtained from the Test solutionand the Standard solution,respectively.
Water,Method Ia á921ñ: not more than 5.0%.
Limit of residual solvents—
Standard solution— Dissolve accurately measured quantities of methanol and methylene chloride in dimethylformamide to obtain a solution having known concentrations of about 5µg of each per mL.
Test solution— Finely powder 10Tablets,and quantitatively transfer the powder to a 50-mLvolumetric flask.Add about 30mLof dimethylformamide,shake by mechanical means for 60minutes,and sonicate for 2minutes.Dilute with dimethylformamide to volume,and mix.Centrifuge a portion of the solution at about 2500rpm for 20minutes,and use the clear supernatant.
Chromatographic system(seeChromatography á621ñ) The gas chromatograph is equipped with a flame-ionization detector and a 2-mm ×3-m glass column containing 0.2%phase G39on support S7.The injection port and detector temperatures are maintained at about 170and 300,respectively.The column temperature is programmed as follows.Initially it is maintained at 75for 10minutes,then increased at a rate of 20per minute to 155,and maintained at 155for 30minutes.The carrier gas is helium,flowing at a rate of about 10mLper minute.
Procedure— Separately inject equal volumes (about 2µL)of the Test solutionand the Standard solutioninto the chromatograph,record the chromatograms,and measure the peak responses.Calculate the amount,in µg,of methylene chloride and methanol in each Tablet taken by the formula:
5C(rU/rS),
in which Cis the concentration,in µg per mL,of methylene chloride or methanol in the Standard solution;and rUand rSare the responses of the corresponding analyte obtained from the Test solutionand the Standard solution,respectively:not more than 23µg of methylene chloride per Tablet is found;and not more than 100µg of methanol per Tablet is found.
Chromatographic purity— Not more than 0.2%of any individual impurity is found;and not more than 0.5%of total impurities is found,the results from both Test 1and Test 2being used.
TEST1—
Mobile phaseand Chromatographic system— Prepare as directed in the Assay.
System suitability solution— Dissolve suitable quantities of phenytoin and USP Carbamazepine RSin methanol to obtain a solution containing about 0.6and 0.2mg per mL,respectively.Dilute this solution quantitatively,and stepwise if necessary,with methanol to obtain a solution containing about 60µg of phenytoin and 20µg of USP Carbamazepine RSper mL.
Standard solution— Dissolve an accurately weighed quantity of USP Carbamazepine RSin methanol,and dilute quantitatively,and stepwise if necessary,with methanol to obtain a solution having a known concentration of about 4µg per mL.
Test solution— Use the Assay stock preparation.
Procedure— Separately inject equal volumes (about 10µL)of the Test solutionand the Standard solutioninto the chromatograph,record the chromatograms,and measure the peak responses.Calculate the percentage of each impurity in the portion of Tablets taken by the formula:
100(CS/CT)(ri/rS),
in which CSis the concentration,in mg per mL,of USP Carbamazepine RSin the Standard solution;CTis the concentration,in mg per mL,of carbamazepine in the Test solution;riis the peak response of each impurity obtained from the Test solution;and rSis the peak response for carbamazepine obtained from the Standard solution.
TEST2—
Mobile phase— Prepare a filtered and degassed mixture of water,methanol,and acetonitrile (10:7:3).Make adjustments if necessary (see System Suitabilityunder Chromatography á621ñ).
System suitability solution— Dissolve suitable quantities of iminostilbene and USP Carbamazepine RSin methanol to obtain a solution containing about 12.5and 5.0µg per mL,respectively.
Standard solution— Use the Standard solution,prepared as directed for Test 1.
Test solution— Use the Assay stock preparation.
Chromatographic system(see Chromatography á621ñ) Prepare as directed in the Assay.Chromatograph the System suitability solution,and record the peak responses as directed for Procedure:the relative retention times are about 0.3for carbamazepine and 1.0for iminostilbene;the resolution,R,between carbamazepine and iminostilbene is not less than 10.0;and the relative standard deviation for replicate injections is not more than 2.0%.
Procedure— Proceed as directed for Test 1.
Assay—
Mobile phase— Prepare a filtered and degassed mixture of water,methanol,and methylene chloride (600:450:45).Make adjustments if necessary (see System Suitabilityunder Chromatography á621ñ).
Internal standard solution— Prepare a solution of phenytoin in methanol containing about 600µg per mL.
Standard preparation— Dissolve an accurately weighed quantity of USP Carbamazepine RSin methanol,and dilute quantitatively,and stepwise if necessary,with methanol to obtain a solution having a known concentration of about 200µg per mL.Pipet 10.0mLof this solution into a conical flask,add 10.0mLof Internal standard solution,mix,and filter.This solution contains about 100µg of USP Carbamazepine RSper mL.
System suitability solution— Pipet equal volumes of Internal standard solutionand Standard preparationinto a suitable flask,and mix.
Assay stock preparation— Finely powder 10Tablets,and quantitatively transfer the powder,with the aid of alcohol,to a volumetric flask of such volume that when the solution is diluted to volume a final concentration estimated to be about 4mg of carbamazepine per mLis obtained.Shake by mechanical means for 60minutes.Sonicate for 15minutes,and dilute with methanol to volume.Allow to stand for 10to 15minutes,then filter a portion of the supernatant,and use the clear filtrate.
Assay preparation— Transfer 5.0mLof the Assay stock preparationto a 100-mLvolumetric flask,dilute with methanol to volume,and mix.Pipet 10.0mLof this solution into a conical flask,add 10.0mLof Internal standard solution,mix,and filter.
Chromatographic system(see Chromatography á621ñ) The liquid chromatograph is equipped with a 230-nm detector,a 4.6-mm ×30-mm guard column that contains 7-µm packing L7,and a 3.9-mm ×30-cm column that contains packing L1.[NOTE—Wash the column with 50to 100mLof methanol before and after use.]The flow rate is about 2mLper minute.Chromatograph the System suitability solution,and record the peak responses as directed for Procedure:the relative retention times are about 0.8for phenytoin,and 1.0for carbamazepine;the resolution,R,between phenytoin and carbamazepine is not less than 2.8;and the relative standard deviation for replicate injections is not more than 2.0%.
Procedure— Separately inject equal volumes (about 10µL)of the Standard preparationand the Assay preparationinto the chromatograph,record the chromatograms,and measure the peak responses.Calculate the quantity,in mg,of carbamazepine (C15H12N2O)in each Tablet taken by the formula:
0.004(CV)(RU/RS),
in which Cis the concentration,in µg per mL,of USP Carbamazepine RSin the Standard preparation;Vis the volume,in mL,of the volumetric flask used to prepare the Assay stock preparation;and RUand RSare the peak response ratios of carbamazepine to the internal standard obtained from the Assay preparationand the Standard preparation,respectively.
Auxiliary Information— Staff Liaison:Ravi Ravichandran,Ph.D.,Senior Scientist
Expert Committee:(PA3)Pharmaceutical Analysis 3
USP28–NF23Page 343
Pharmacopeial Forum:Volume No.28(3)Page 746
Phone Number:1-301-816-8330